EGFR and non-small cell lung carcinoma: A clinical trial for patients with EGFR inhibitor-resistant NSCLC at doses of 20 to 240 mg once daily revealed that diarrhea is the most common toxicity, followed by rash, nausea, and decreased appetite (24).